Seizure Forecasting Using a Novel Sub-Scalp Ultra-Long Term EEG Monitoring System

Abstract

Accurate identification of seizure activity, both clinical and subclinical, has important implications in the management of epilepsy. Accurate recognition of seizure activity is essential for diagnostic, management and forecasting purposes, but patient-reported seizures have been shown to be unreliable. Earlier work has revealed accurate capture of electrographic seizures and forecasting is possible with an implantable intracranial device, but less invasive electroencephalography (EEG) recording systems would be optimal. Here, we present preliminary results of seizure detection and forecasting with a minimally invasive sub-scalp device that continuously records EEG. Five participants with refractory epilepsy who experience at least two clinically identifiable seizures monthly have been implanted with sub-scalp devices (Minder®), providing two channels of data from both hemispheres of the brain. Data is continuously captured via a behind-the-ear system, which also powers the device, and transferred wirelessly to a mobile phone, from where it is accessible remotely via cloud storage. EEG recordings from the sub-scalp device were compared to data recorded from a conventional system during a 1-week ambulatory video-EEG monitoring session. Suspect epileptiform activity (EA) was detected using machine learning algorithms and reviewed by trained neurophysiologists. Seizure forecasting was demonstrated retrospectively by utilizing cycles in EA and previous seizure times. The procedures and devices were well-tolerated and no significant complications have been reported. Seizures were accurately identified on the sub-scalp system, as visually confirmed by periods of concurrent conventional scalp EEG recordings. The data acquired also allowed seizure forecasting to be successfully undertaken. The area under the receiver operating characteristic curve (AUC score) achieved (0.88), which is comparable to the best score in recent, state-of-the-art forecasting work using intracranial EEG.

Noninvasive mobile EEG as a tool for seizure monitoring and management: A systematic review

“…For example, a reliable method for detecting counting seizures using mobile EEG would introduce the opportunity to pre-emptively modify treatment regimens or plan the optimal timing for diagnostic studies. 74 Repeated long-term at-home recordings could allow seizure forecasting, and identification of seizures pattern and cycles, [75][76][77][78] which may enable a better understanding of the individual seizure risk over time and improve patients' quality of life. 79,80…”

Dogs as a Natural Animal Model of Epilepsy

“…In connection with an external recorder (the 24/7 EEG TM SubQ) combined with a complete data infrastructure and analytics software, the implanted electrode provides continuous (24/7) and automated electrographic seizure detection for up to 15 months (358)(359)(360). Several similar subscalp systems have been developed and tested in humans, including the use of such systems for seizure forecasting (359,361). The size of the subcutaneous needle electrode or subscalp device of the UNEEG system would be ideally suited for continuous EEG recordings in epileptic dogs, which we plan to explore soon.…”

Medicom Conference Report EAN 2022

“…Another example is the Chronic Migraine Epidemiology and Outcomes (CaMEO) study, which assessed barriers to good medical care for chronic migraine [4]. Of 1,254 included patients, only <5% with chronic migraine traversed the 3 barriers -medical consultation, accurate diagnosis, and minimal pharmacologic treatment-to receiving proper care.…”

“…Results of an open-label study with 263 migraine patients suggested that sTMS may be an effective, well-tolerated treatment option for migraine prevention [4]. A very recently published open-label study suggests that sTMS may be an effective, well-tolerated treatment option for the long-term prevention of difficult-to-treat, high-frequency episodic migraine and chronic migraine [5].…”

“…Magyari also addressed the question when to stop MS therapy. Reasons to do this include long disease duration, lack of relapses and of MRI activity, progression to secondaryprogressive MS (SPMS) with very slow progression, safety issues, and access-related issues [4]. There are legitimate arguments for and against continuing DMT [5].…”